Dr. William K. Oh is Clinical Professor of Medicine in the Division of Hematology and Medical Oncology at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai. He is an expert in the management of genitourinary malignancies. He was recently the inaugural Chief Medical Officer at Prostate Cancer Foundation (PCF), where he built an implementation science platform to address prostate cancer mortality, resulting in the publication of the first-ever “PCF Screening Guidelines for Black Men in the US” in NEJM Evidence in May 2024. From 2021-2022, he was CMO at Sema4, a publicly-traded, patient-centered health intelligence company that used genomics and RWE/AI to develop algorithms to improve rare disease and cancer care. At Sema4, he launched clinical protocols and health system partnerships to improve understanding of genomic testing by tying molecular insights to clinical data extracted by ML/AI from EHRs.
Dr. Oh is Founding Chair of the Scientific Advisory Board of Archetype Therapeutics, a startup using a novel AI-generated modeling platform to screen billions of drugs to predict the best candidates for unmet medical needs in cancer. He is also Chair of the SAB for NTx Bio, a biomanufacturing startup building systems to produce personalized mRNA vaccines in sustainable, scalable devices. He serves as Board Member and Chair of the Medical Advisory Council for the Chemotherapy+ Foundation in NYC.
From 2009-2020, Dr. Oh was System Chief of Hematology and Medical Oncology at the Mount Sinai Health System, the Ezra Greenspan, MD Professor in Clinical Cancer Therapeutics and Associate and Deputy Director of The Tisch Cancer Institute at Mount Sinai, for which he helped to achieve and renew NCI designation. Prior to that, he spent 14 years at Harvard Medical School and Dana-Farber Cancer Institute in Boston, including as Clinical Director of GU Oncology, Associate Professor of Medicine, Director of the Gelb Center for Translational Medicine and Founding Chair of the Harvard Cancer Center Data and Safety Monitoring Committee.
Dr. Oh has authored over 350 original articles, reviews and chapters. He has edited 3 books on prostate cancer and served in key roles for the ASCO, ACS, AJCC and AUA. He is an inductee of American Society for Clinical Investigation and has been continuously selected as a Top Doctor in New York Magazine, Castle Connolly, Best Doctors and Super Doctors from 2010 to 2024. He has been honored as a Top AAPI Doctor in 2023 and 2024.
Dr. Oh graduated from Yale College with a BS in MB&B and received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital in Boston and fellowship in medical oncology at Dana-Farber Cancer Institute in 1997.